Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2023 - 2024)

Spyre Therapeutics (SYRE) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $253.4 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Preferred Stock Liabilities changed N/A year-over-year to $253.4 million, compared with a TTM value of $253.4 million through Mar 2024, changed N/A, and an annual FY2023 reading of $84.6 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $253.4 million for Q1 2024 at Spyre Therapeutics, up from $84.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $387.1 million in Q3 2023 and bottomed at $84.6 million in Q4 2023.